Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES IN NOVEMBER 2025:

PYXIS ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

- PRELIMINARY DATA FROM ONGOING PHASE 1 CLINICAL STUDIES OF MICVOTABART PELIDOTIN (MICVO) IN PATIENTS WITH RECURRENT AND METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) EXPECTED IN THE FOURTH QUARTER OF 2025 - CLINICAL UPDATE TO FOCUS ON PRELIMINARY DATA FROM PHASE 1 MONOTHERAPY DOSE EXPANSION STUDY OF MICVO IN 2L/3L R/M HNSCC PATIENTS, INCLUDING FROM BOTH POST PLATINUM & PD-1 AND POST EGFR & PD-1 ARMS, AND PRELIMINARY DATA FROM PHASE 1/2 COMBINATION DOSE ESCALATION STUDY OF MICVO AND KEYTRUDA (PEMBROLIZUMAB) IN 1L/2L+ R/M HNSCC PATIENTS - PRESENTED TRANSLATIONAL DATA AT ESMO 2025 AND AACR-NCI-EORTC PROVIDING MEANINGFUL INSIGHTS INTO MICVO'S FIRST-IN-CONCEPT NON-CELLULAR TARGETING ANTIBODY DRUG CONJUGATE (ADC) MECHANISM OF ACTION - EXPECTED CASH RUNWAY THROUGH DATA MILESTONES AND INTO THE SECOND HALF OF 2026 BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY PROVIDED A BUSINESS UPDATE, AND REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025. IN THE DYNAMIC LANDSCAPE OF EMERGING CLINICAL-STAGE THERAPIES FOR PATIENTS WITH RECURRENT AND METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA, A SIGNIFICANT UNMET MEDICAL NEED REMAINS DESPITE THE POTENTIAL IMPROVEMENTS IN TREATMENT OPTIONS, SAID LARA S.

PYXIS ONCOLOGY PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

TRANSLATIONAL DATA VALIDATE MECHANISM OF FIRST-IN-CONCEPT EXTRACELLULAR-CLEAVING ADC MICVOTABART PELIDOTIN (MICVO) MICVO COMBATS SOLID TUMORS THROUGH THREE-PRONGED MECHANISM OF ACTION: DIRECT TUMOR CELL KILLING, BYSTANDER EFFECT, AND IMMUNOGENIC CELL DEATH FINDINGS DEMONSTRATE MICVO'S EFFECTS ON TUMOR MICROENVIRONMENT REMODELING AND IMMUNE ACTIVATION TRANSLATIONAL DATA TO BE PRESENTED IN TWO POSTERS AT ESMO 2025 AND SIX POSTERS AT AACR-NCI-EORTC BOSTON, OCT. 13, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, ANNOUNCED TODAY THAT IT WILL PRESENT TRANSLATIONAL DATA FOR MICVOTABART PELIDOTIN (MICVO), A FIRST-IN-CONCEPT ANTIBODY-DRUG CONJUGATE (ADC) THAT CLEAVES IN THE EXTRACELLULAR MATRIX AND TARGETS EXTRADOMAIN-B OF FIBRONECTIN (EDB+FN), AT UPCOMING MEDICAL MEETINGS. DATA WILL BE PRESENTED AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2025 IN BERLIN, GERMANY (OCTOBER 17-21, 2025), AND AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE IN BOSTON, MASSACHUSETTS (OCTOBER 22-26, 2025).

PYXIS ONCOLOGY TO PRESENT TRANSLATIONAL DATA AND KEY BIOLOGY FINDINGS ELUCIDATING THE MECHANISM OF ACTION OF MICVO AT UPCOMING MEDICAL MEETINGS

BOSTON, OCT. 09, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING ANTIBODY-DRUG CONJUGATE (ADC) THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF ALEX KANE, MBA, AS SENIOR VICE PRESIDENT, INVESTOR RELATIONS & CAPITAL MARKETS, EFFECTIVE IMMEDIATELY.

PYXIS ONCOLOGY APPOINTS ALEX KANE AS SENIOR VICE PRESIDENT, INVESTOR RELATIONS & CAPITAL MARKETS

BOSTON, SEPT. 30, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION ANTIBODY-DRUG CONJUGATE (ADC') THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, REPORTED TODAY THAT PYXIS ONCOLOGY'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 382,518 SHARES OF PYXIS ONCOLOGY'S COMMON STOCK TO SEVEN NEWLY HIRED EMPLOYEES. THE AWARDS WERE GRANTED UNDER THE PYXIS ONCOLOGY, INC. 2022 INDUCEMENT PLAN (THE PLAN') WITH A GRANT DATE OF SEPTEMBER 30, 2025, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEE ENTERING EMPLOYMENT WITH PYXIS ONCOLOGY, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

PYXIS ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOSTON, AUG. 21, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING ANTIBODY-DRUG CONJUGATE (ADC) THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THAT LARA S. SULLIVAN, M.D., PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHIEF MEDICAL OFFICER, WILL PARTICIPATE IN THE FOLLOWING UPCOMING CONFERENCES.

PYXIS ONCOLOGY TO PARTICIPATE IN SEPTEMBER INVESTOR AND INDUSTRY CONFERENCES

 PHASE 1 MONOTHERAPY EXPANSION STUDY OF MICVOTABART PELIDOTIN (MICVO) FOR RECURRENT AND METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) PATIENTS PROGRESSING WELL WITH PRELIMINARY DATA IN SECOND HALF OF 2025 AND FIRST HALF OF 2026

PYXIS ONCOLOGY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOSTON, JUNE 30, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION ANTIBODY-DRUG CONJUGATE (ADC') THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, REPORTED TODAY THAT PYXIS ONCOLOGY'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 246,238 SHARES OF PYXIS ONCOLOGY'S COMMON STOCK TO FOUR NEWLY HIRED EMPLOYEES. THE AWARDS WERE GRANTED UNDER THE PYXIS ONCOLOGY, INC. 2022 INDUCEMENT PLAN (THE PLAN') WITH A GRANT DATE OF JUNE 30, 2025, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEE ENTERING EMPLOYMENT WITH PYXIS ONCOLOGY, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

- ANNOUNCED ROBUST PRECLINICAL DATA SUPPORTING THE UNIQUE THREE-PRONGED MECHANISM OF ACTION OF MICVOTABART PELIDOTIN (MICVO, FORMERLY PYX-201), DRIVING ANTI-TUMOR ACTIVITY VIA DIRECT TUMOR KILLING, BYSTANDER EFFECT AND IMMUNOGENIC CELL DEATH

PYXIS ONCOLOGY REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOSTON, MAY 14, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION ADC THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THAT LARA S. SULLIVAN, M.D., PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHIEF MEDICAL OFFICER, WILL PARTICIPATE IN FIRESIDE CHATS AND BE AVAILABLE FOR ONE-ON-ONE MEETINGS WITH INVESTORS AT THE FOLLOWING TWO UPCOMING INVESTOR CONFERENCES.

PYXIS ONCOLOGY TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

GENE SIGNATURES ASSOCIATED WITH INCREASED EFFICACY OF MICVOTABART PELIDOTIN (MICVO) DUE TO GREATER LINKER CLEAVAGE WERE IDENTIFIED BASED ON DIFFERENTIAL GENE EXPRESSION ANALYSIS OF PDX RESPONDERS/NON-RESPONDERS

PYXIS ONCOLOGY PRESENTS PROMISING PRECLINICAL RESULTS PROVIDING PROOF OF MECHANISM OF MICVOTABART PELIDOTIN, THE FIRST-IN-CONCEPT EXTRACELLULAR-TARGETING ADC

BOSTON, APRIL 02, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THAT LARA S. SULLIVAN, M.D., PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHIEF MEDICAL OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE STIFEL 2025 VIRTUAL TARGETED ONCOLOGY FORUM ON WEDNESDAY, APRIL 9, 2025, AT 11:30 A.M. ET. THE COMPANY WILL ALSO BE HOLDING ONE-ON-ONE INVESTOR MEETINGS AT THE EVENT.

Pyxis Oncology, Inc.

PYXS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Pyxis Oncology, Inc.

PYXS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PYXS